A 52-year-old man with a 10-year history of Type 2 diabetes presents for routine follow-up. His fasting glucose is 156 mg/dL and HbA1c is 7.8%. He is currently on metformin and glibenclamide. To assess his current risk of microvascular complications and guide intensification of therapy, which investigation is most appropriate?

Explanation

## Assessing Microvascular Complications in Type 2 Diabetes **Key Point:** 24-hour urinary albumin excretion (or spot urine albumin-to-creatinine ratio) is the most appropriate investigation to assess current microvascular complications and guide therapy intensification in Type 2 diabetes. ### Why Urinary Albumin Excretion? **Albuminuria is the earliest marker of diabetic nephropathy** — the most common microvascular complication: - **Microalbuminuria** (30–300 mg/day or 30–300 mg/g creatinine) indicates early glomerular damage - **Macroalbuminuria** (>300 mg/day) indicates advanced nephropathy - Presence of albuminuria **independently predicts cardiovascular risk** and progression to end-stage renal disease ### Clinical Significance in This Patient With 10 years of diabetes and suboptimal glycemic control (HbA1c 7.8%), this patient is at **high risk for microvascular complications**. Screening for albuminuria is essential to: 1. Detect early nephropathy 2. Initiate **ACE inhibitor or ARB therapy** (renoprotective, regardless of blood pressure) 3. Guide intensification of glycemic control 4. Assess need for additional cardiovascular risk reduction | Investigation | Purpose | Frequency | |---|---|---| | **24-h urinary albumin or spot ACR** | Detect diabetic nephropathy | Annual (at diagnosis and yearly thereafter) | | **Serum creatinine / eGFR** | Assess renal function | Annual | | **Dilated retinal exam** | Screen for retinopathy | Annual | | **Monofilament testing** | Screen for neuropathy | Annual | **Clinical Pearl:** The **spot urine albumin-to-creatinine ratio (ACR)** is now preferred over 24-hour urine collection in clinical practice because it is: - More convenient for patients - Equally sensitive and specific - Less prone to collection errors **High-Yield:** Presence of albuminuria in Type 2 diabetes mandates: - ACE inhibitor or ARB (even if normotensive) - Intensified glycemic control (target HbA1c <7%) - Blood pressure control (target <130/80 mmHg per ADA/ACC guidelines) - Statin therapy for cardiovascular protection ### Why Other Investigations Are Inappropriate **Serum fructosamine** — Reflects glycemic control over 2–3 weeks; useful for monitoring short-term glycemic trends but does not assess complications. **Glycated albumin** — Similar to fructosamine; intermediate-term glycemic marker (2–3 weeks), not a complication-screening test. **Repeat HbA1c in 3 months** — Appropriate for monitoring glycemic response to therapy changes, but does not assess current microvascular complications.